Top-News
Professionelle Dienstleistungen Schweden

PMD Device Solutions AB News

Aktie
WKN:  A401UE ISIN:  SE0021513645
0,61 €
-0,025 €
-3,94%
17.05.24 15:57:13
Handeln Depot/Watchlist
Aktienanzahl *
20,59 Mio.
Marktkapitalisierung *
12,77 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 05.02.2024

PMD Device Solutions AB News

30.08.22 - ACCESSWIRE
Promore Pharma Interim report January – June 2022
STOCKHOLM, SWEDEN / ACCESSWIRE / August 30, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)
23.08.22 - ACCESSWIRE
Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022
STOCKHOLM, SWEDEN / ACCESSWIRE / August 23, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)
10.08.22 - ACCESSWIRE
Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds
STOCKHOLM, SE / ACCESSWIRE / August 10, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0)
13.06.22 - ACCESSWIRE
The Last Clinic Visit Conducted in Promore Pharma's Phase II Study of Ensereptide
STOCKHOLM, SE / ACCESSWIRE / June 13, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0)
17.05.22 - ACCESSWIRE
Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022
STOCKHOLM, SWEDEN / ACCESSWIRE / May 17, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0)
17.05.22 - ACCESSWIRE
Promore Pharma -- Interim Report January-March 2022
STOCKHOLM, SWEDEN / ACCESSWIRE / May 17, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)
13.05.22 - ACCESSWIRE
Invitation to Conference Call Regarding Promore Pharma’s Interim Report for the First Quarter 2022
STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)
26.04.22 - ACCESSWIRE
Promore Pharma's Annual Report 2021 and AGM related Documents Published
STOCKHOLM, SE / ACCESSWIRE / April 26, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0)
12.04.22 - ACCESSWIRE
Notice of Annual General Meeting Promore Pharma AB (publ)
STOCKHOLM, SWEDEN / ACCESSWIRE / April 12, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)
17.03.22 - ACCESSWIRE
Promore Pharma has Reached Recruitment Goal in Clinical Trial of Ensereptide
STOCKHOLM, SWEDEN / ACCESSWIRE / March 17, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0)
16.02.22 - ACCESSWIRE
Interim Report January - December 2021
STOCKHOLM, SWEDEN / ACCESSWIRE / February 16, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)
16.02.22 - ACCESSWIRE
First Patient Recruited to Promore Pharma's Clinical Trial Regarding Scarring According to Plan
STOCKHOLM, SWEDEN / ACCESSWIRE / February 16, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)
09.02.22 - ACCESSWIRE
Invitation to Conference Call Regarding Promore Pharma’s Year-end Report 2021
STOCKHOLM, SWEDEN / ACCESSWIRE / February 9, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0)
31.01.22 - ACCESSWIRE
Promore Pharma Deregisters Warrants
STOCKHOLM, SWEDEN / ACCESSWIRE / January 31, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)
08.12.21 - ACCESSWIRE
Promore Pharma Granted US Patent Regarding Treatment Of Chronic Wounds
STOCKHOLM, SWEDEN / ACCESSWIRE / December 08, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
23.11.21 - ACCESSWIRE
Interim Report January - September 2021
STOCKHOLM, SE / ACCESSWIRE / November 23, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
19.11.21 - ACCESSWIRE
Invitation to Conference Call Regarding Promore Pharma’s Interim Report for the Third Quarter 2021
STOCKHOLM, SE / ACCESSWIRE / November 19, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
16.11.21 - ACCESSWIRE
Nomination Committee Appointed for the Annual General Meeting 2022 in Promore Pharma
STOCKHOLM, SE / ACCESSWIRE / November 16, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
09.11.21 - ACCESSWIRE
Promore Pharma Receives Permits to Start a Phase II Clinical Trial Regarding Scar Prevention
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
25.10.21 - ACCESSWIRE
Promore Pharma Announces that Scientific Article has Been Published on Clinical Study Results with Ropocamptide for Venous Leg Ulcers
STOCKHOLM, SE / ACCESSWIRE / October 25, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)

Newssuche

Videos

newspaper
17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »